Whalesbook
Retatrutide Sets New Weight Loss Benchmark
Eli Lilly and Company's investigational drug retatrutide achieved a remarkable 28.3% average weight loss in its Phase 3 TRIUMPH-1 trial over 80 weeks. This performance significantly outperforms existing weight-loss medications and approaches the efficacy of bariatric surgery. The "triple G" drug, which targets GLP-1, GIP, and glucagon hormone receptors, showed that the 12 mg dose resulted in 70.3 pounds of weight loss for participants. More than 45% of patients on this highest dose achieved over 30% weight loss. An extension study indicated a 30.3% loss at 104 weeks for those with a baseline BMI of 35 or higher. For comparison, Lilly's Zepbound and Novo Nordisk's Wegovy have shown weight loss in the range of 15-21% in trials. Analysts from Truist Securities have called these data a "new benchmark for anti-obesity medications," estimating peak sales for retatrutide between $12 and $19 billion. BMO Capital Markets anticipates a 2027 launch for the drug.
Safety and Competition in the Obesity Drug Market
The safety profile of retatrutide appears consistent with other incretin-based therapies, though adverse events require monitoring. The most common side effects included nausea (42.4% at 12 mg), diarrhea (32%), and constipation (26.1%). Dysesthesia, an abnormal skin sensation, was reported in 12.5% of patients on the highest dose, a slight decrease from prior trials. Discontinuation rates due to adverse events at the 12 mg dose were 11.3%, compared to 4.9% for placebo. Retatrutide faces intense competition in the burgeoning obesity drug market, projected to reach $66 billion in 2025 and $92 billion in 2026. Novo Nordisk, a key rival, recently presented data showing early responders to a higher dose of Wegovy (semaglutide 7.2 mg) achieved 27.7% weight loss in the STEP UP trial. The oral version of Wegovy was approved in late 2025, offering an alternative to injectables.
Analyst Sentiment and Valuation
Eli Lilly (LLY) currently holds a market capitalization of approximately $959 billion with a P/E ratio of 36.68. In contrast, Novo Nordisk (NVO) has a P/E ratio of 10.38 as of May 2026. Analysts maintain a positive outlook on Eli Lilly, with Truist Securities reiterating a "Buy" rating and a $1,281 price target following the retatrutide trial results. Other firms like BMO Capital and Wells Fargo also hold "Outperform" or "Overweight" ratings. Analysts view retatrutide's performance as a significant catalyst that will support its approval and adoption, particularly for patients not adequately served by current treatments. A projected launch for retatrutide is anticipated by late 2027 to mid-2028, contingent on regulatory review.
Potential Concerns and Valuation Considerations
Despite the impressive efficacy, the discontinuation rate due to adverse events for retatrutide at the highest dose (11.3%) remains a point of consideration, even if comparable to other incretin therapies. While Lilly states the safety profile is comparable to other GLP-1 medications, the higher incidence of adverse events leading to discontinuation at higher doses warrants close monitoring post-approval. The potential for weight regain after cessation of treatment is a known challenge across the weight-loss drug class, including for retatrutide, Zepbound, and Wegovy. Furthermore, the current valuation of Eli Lilly, with a Shiller PE Ratio of 109.59, significantly above its 10-year median, suggests a high growth expectation already priced into the stock, making it vulnerable to any perceived setbacks in retatrutide's regulatory or commercial rollout. Competitor Novo Nordisk, with a P/E ratio of 10.38, appears significantly more attractively valued based on current earnings.
Future Market Impact
Eli Lilly aims to seek regulatory approval and launch retatrutide next year, positioning it to capture a substantial share of the rapidly expanding obesity market, which is projected to reach $92 billion in 2026 alone. The drug's ability to achieve weight loss akin to bariatric surgery could redefine treatment standards. However, the ultimate market impact will depend on its long-term safety profile, tolerability across different patient populations, and successful navigation of the competitive landscape, particularly against Novo Nordisk's established and evolving Wegovy franchise.